The University of Virginia seeks adult women ages 18 years and older with recurrent or metastatic cervical cancer.
You may be eligible for this study if:
• You have squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
• You have had one or more prior lines of systemic platinum chemotherapy and prior immunotherapy
You will be randomized (assigned by chance) to one of two treatment arms,
• Arm 1: MK2870 4mg/kg administered intravenously
• Arm2: Treatment of Physician’s choice consisting of one of the following: Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan.
This study involves blood draw, imaging of the chest, abdomen and pelvis, electrocardiogram (ECG), Echocardiogram (ECHO) and archival tissue collection.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
No Compensation